Edward B. Skibo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Edward B. Skibo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Chengguo Xing
Department of Chemistry and Biochemistry, Arizona State University, Tempe, Arizona 85287-1604
2 shared publicationsRobert T. Dorr
Arizona Cancer Center, School of Medicine, University of Arizona, Tucson, Arizona 85724
2 shared publicationsXiaofen Huang
Department of Chemistry and Biochemistry, Arizona State University, Tempe, Arizona
2 shared publications- Akmal Jamil
Department of Chemistry, College of Science, University of Hafr Al Batin
1 shared publication Armand Ghodousi
Department of Chemistry and Biochemistry, Arizona State University, Tempe, Arizona 85287-1604
1 shared publicationBrittany Austin
Department of Chemistry and Biochemistry, Arizona State University, Tempe, Arizona 85287-1604
1 shared publication
Latest Publications
- 28 January 2010
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 8 (7) , 1577-1587
Triple molecular target approach to selective melanoma cytotoxicity
Phenylalanine-linked pyrrolo[1,2-a]benzimidazoles were successfully designed to target melanoma cells in vitro. Our design utilised three molecular targets: a phenylalanine pump, the reducing enzyme DT-diaphorase, and IMP dehydrogenase. We describe the synthesis of these compounds as well as the results of in vitro, in vivo, and QSAR studies.
- 28 January 2010
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 8 (7) , 1577-1587
Triple molecular target approach to selective melanoma cytotoxicity
Phenylalanine-linked pyrrolo[1,2-a]benzimidazoles were successfully designed to target melanoma cells in vitro. Our design utilised three molecular targets: a phenylalanine pump, the reducing enzyme DT-diaphorase, and IMP dehydrogenase. We describe the synthesis of these compounds as well as the results of in vitro, in vivo, and QSAR studies.
- 7 April 2009
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 7 (10) , 2140-2154
Quinone methide chemistry of prekinamycins: 13C- labeling, spectral global fitting and in vitro studies
In this article, we address the presence of the prekinamycin quinone methide using the techniques of spectral global fitting and the13C-labeling of the reactive centre. Two-electron reduction of a prekinamycin affords a long-lived quinone methide species that was characterised spectrally. A correlation was made between the calculated ΔE (kcal/mol) values for quinone methide tautomerisation and cytostatic activity to support the postulate that the quinone methide plays a role in prekinamycin biological activity. We also prepared a stable quinone methide of prekinamycin and studied its solution chemistry directly.
- 7 April 2009
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 7 (10) , 2140-2154
Quinone methide chemistry of prekinamycins: 13C- labeling, spectral global fitting and in vitro studies
In this article, we address the presence of the prekinamycin quinone methide using the techniques of spectral global fitting and the13C-labeling of the reactive centre. Two-electron reduction of a prekinamycin affords a long-lived quinone methide species that was characterised spectrally. A correlation was made between the calculated ΔE (kcal/mol) values for quinone methide tautomerisation and cytostatic activity to support the postulate that the quinone methide plays a role in prekinamycin biological activity. We also prepared a stable quinone methide of prekinamycin and studied its solution chemistry directly.
- 16 July 2008
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 6 (17) , 3059-3064
Synthesis and in vitro evaluation of imidazole-based wakayin analogues
Analogues of wakayin based on diimidazo[1,5,4-de, 1,5,4-h]-quinoxaline have been prepared and evaluated with respect to cytostatic and cytotoxic activity. Assays in a 60-cell-line human cancer panel revealed selective activity against cells with the VEGF (Flt-1) receptor.
- 16 July 2008
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 6 (17) , 3059-3064
Synthesis and in vitro evaluation of imidazole-based wakayin analogues
Analogues of wakayin based on diimidazo[1,5,4-de, 1,5,4-h]-quinoxaline have been prepared and evaluated with respect to cytostatic and cytotoxic activity. Assays in a 60-cell-line human cancer panel revealed selective activity against cells with the VEGF (Flt-1) receptor.
- 5 November 2002
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (25) , 5543-5555
Pyrimidoquinazoline-Based Antitumor Agents. Design of Topoisomerase II to DNA Cross-linkers with Activity against Protein Kinases
A series of pyrimidoquinazoline analogues, possessing either 4,5-g or 5,4-g fusion, were studied with respect to cytotoxicity, topoisomerase II inhibitory activity, in vivo activity, and DNA cleavage and DNA−protein cross-linking properties. These analogues were designed as electron-deficient anthraquinones with dual alkylating centers to cross-link DNA with topoisomerase II. Our studies verified the presence of DNA−protein cross-linking in vitro as well as topoisomerase II poisoning by pyrimidoquinazoline analogues. In addition, COMPARE analysis revealed that the pyrimidoquinazolines possess inhibitory activity against both topoisomerase II and protein kinases, such as the paullones, a dual property observed in other antineoplastic agents influencing phosphoester transfer.
- 5 November 2002
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (25) , 5543-5555
Pyrimidoquinazoline-Based Antitumor Agents. Design of Topoisomerase II to DNA Cross-linkers with Activity against Protein Kinases
A series of pyrimidoquinazoline analogues, possessing either 4,5-g or 5,4-g fusion, were studied with respect to cytotoxicity, topoisomerase II inhibitory activity, in vivo activity, and DNA cleavage and DNA−protein cross-linking properties. These analogues were designed as electron-deficient anthraquinones with dual alkylating centers to cross-link DNA with topoisomerase II. Our studies verified the presence of DNA−protein cross-linking in vitro as well as topoisomerase II poisoning by pyrimidoquinazoline analogues. In addition, COMPARE analysis revealed that the pyrimidoquinazolines possess inhibitory activity against both topoisomerase II and protein kinases, such as the paullones, a dual property observed in other antineoplastic agents influencing phosphoester transfer.
- 1 October 2001
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 44 (22) , 3545-3562
Aziridinyl Quinone Antitumor Agents Based on Indoles and Cyclopent[b]indoles: Structure−Activity Relationships for Cytotoxicity and Antitumor Activity
A large number of aziridinyl quinones represented by series 1 − 9 were studied with respect to their DT-diaphorase substrate activity, DNA reductive alkylation, cytostatic/cytotoxic activity, and in vivo activity. As a result, generalizations have been made with respect with respect to the following: DT-diaphorase substrate design, DT-diaphorase−cytotoxicity quantitative structure−activity relationship (QSAR), and DNA reductive alkylating agent design. A saturating relationship exists between the substrate specificity for human recombinant DT-diaphorase and the cytotoxicity in the human H460 non-small-cell lung cancer cell line. The interpretation of this relationship is that reductive activation is no longer rate-limiting for substrates with high DT-diaphorase substrate specificities. High DT-diaphorase substrate specificity is not desirable in the indole and cylopent[b]indole systems because of the result is the loss of cancer selectivity along with increased toxicity. We conclude that aziridinyl quinones of this type should possess a substrate specificity (Vmax/KM) < 10 × 10-4 s-1 for DT-diaphorase in order not to be too toxic or nonselective. While some DNA alkylation was required for cytostatic and cytotoxic activity by series 1 − 9, too much alkylation results in loss of cancer selectivity as well as increased in vivo toxicity. Indeed, the most lethal compounds are the indole systems with a leaving group in the 3α-position (like the antitumor agent EO9). We conclude that relatively poor DNA alkylating agents (according to our assay) show the lowest toxicity with the highest antitumor activity.
- 1 October 2001
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 44 (22) , 3545-3562
Aziridinyl Quinone Antitumor Agents Based on Indoles and Cyclopent[b]indoles: Structure−Activity Relationships for Cytotoxicity and Antitumor Activity
A large number of aziridinyl quinones represented by series 1 − 9 were studied with respect to their DT-diaphorase substrate activity, DNA reductive alkylation, cytostatic/cytotoxic activity, and in vivo activity. As a result, generalizations have been made with respect with respect to the following: DT-diaphorase substrate design, DT-diaphorase−cytotoxicity quantitative structure−activity relationship (QSAR), and DNA reductive alkylating agent design. A saturating relationship exists between the substrate specificity for human recombinant DT-diaphorase and the cytotoxicity in the human H460 non-small-cell lung cancer cell line. The interpretation of this relationship is that reductive activation is no longer rate-limiting for substrates with high DT-diaphorase substrate specificities. High DT-diaphorase substrate specificity is not desirable in the indole and cylopent[b]indole systems because of the result is the loss of cancer selectivity along with increased toxicity. We conclude that aziridinyl quinones of this type should possess a substrate specificity (Vmax/KM) < 10 × 10-4 s-1 for DT-diaphorase in order not to be too toxic or nonselective. While some DNA alkylation was required for cytostatic and cytotoxic activity by series 1 − 9, too much alkylation results in loss of cancer selectivity as well as increased in vivo toxicity. Indeed, the most lethal compounds are the indole systems with a leaving group in the 3α-position (like the antitumor agent EO9). We conclude that relatively poor DNA alkylating agents (according to our assay) show the lowest toxicity with the highest antitumor activity.
- 5 September 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 9 (9) , 2445-2459
Recognition and cleavage at the DNA major groove
- 5 September 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 9 (9) , 2445-2459
Recognition and cleavage at the DNA major groove
- 1 October 1998
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 37 (43) , 15199-15213
Chemistry and DNA Alkylation Reactions of Aziridinyl Quinones: Development of an Efficient Alkylating Agent of the Phosphate Backbone
Described herein are detailed hydrolytic studies of a series of aziridinyl quinones, which trap nucleophiles when protonated. This study provided a compilation of the rate constants for nucleophile trapping and of the pKa values for the protonated aziridinyl quinones. A linear free energy relationship, including the antitumor agent DZQ, as well as other synthetic quinone derivatives, was obtained as a result of this study. Protonated DZQ has the relatively high pKa value of 3.8, which explains the enhanced cross-linking of DNA by DZQ and other related aziridinyl quinones at pH 4. The literature often shows aziridinyl quinone protonation occurring at the aziridinyl nitrogen, but the dependence of pKa values on quinone substituents indicates the presence of delocalization, which must arise from O-protonation. Also investigated were the DNA alkylation reactions of protonated aziridinyl quinones. At the outset of this study, we postulated that these “hard” electrophiles would alkylate the phosphate backbone of DNA. Bulk DNA is up to 35% alkylated by protonated aziridinyl quinones as judged by the incorporation of the quinone chromophore into the DNA. The presence of phosphate alkylation was verified by a 1H−31P NMR correlation experiment with DZQ-alkylated hexamer. Our modeling studies present a new picture of DZQ alkylation of DNA, where there is competition between N(7) and phosphate alkylation. The conclusions of this part of our study are that the phosphate backbone should be considered as a possible target of any DNA-alkylating agent and that an assessment of phosphate alkylation is best made with a 1H−31P NMR correlation experiment. Finally, the benzimidazole-based aziridinyl quinone 2 was observed to undergo aziridine ring opening followed by hydrolytic removal of the aminoethyl group from the quinone ring. This reaction was used to tag the phosphate backbone of DNA with aminoethyl groups. Such tags render anionic phosphates cationic and could also be employed as points of attachment for chromophores, spin labels, or other moieties to DNA.
- 1 October 1998
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 37 (43) , 15199-15213
Chemistry and DNA Alkylation Reactions of Aziridinyl Quinones: Development of an Efficient Alkylating Agent of the Phosphate Backbone
Described herein are detailed hydrolytic studies of a series of aziridinyl quinones, which trap nucleophiles when protonated. This study provided a compilation of the rate constants for nucleophile trapping and of the pKa values for the protonated aziridinyl quinones. A linear free energy relationship, including the antitumor agent DZQ, as well as other synthetic quinone derivatives, was obtained as a result of this study. Protonated DZQ has the relatively high pKa value of 3.8, which explains the enhanced cross-linking of DNA by DZQ and other related aziridinyl quinones at pH 4. The literature often shows aziridinyl quinone protonation occurring at the aziridinyl nitrogen, but the dependence of pKa values on quinone substituents indicates the presence of delocalization, which must arise from O-protonation. Also investigated were the DNA alkylation reactions of protonated aziridinyl quinones. At the outset of this study, we postulated that these “hard” electrophiles would alkylate the phosphate backbone of DNA. Bulk DNA is up to 35% alkylated by protonated aziridinyl quinones as judged by the incorporation of the quinone chromophore into the DNA. The presence of phosphate alkylation was verified by a 1H−31P NMR correlation experiment with DZQ-alkylated hexamer. Our modeling studies present a new picture of DZQ alkylation of DNA, where there is competition between N(7) and phosphate alkylation. The conclusions of this part of our study are that the phosphate backbone should be considered as a possible target of any DNA-alkylating agent and that an assessment of phosphate alkylation is best made with a 1H−31P NMR correlation experiment. Finally, the benzimidazole-based aziridinyl quinone 2 was observed to undergo aziridine ring opening followed by hydrolytic removal of the aminoethyl group from the quinone ring. This reaction was used to tag the phosphate backbone of DNA with aminoethyl groups. Such tags render anionic phosphates cationic and could also be employed as points of attachment for chromophores, spin labels, or other moieties to DNA.
- 1 June 1998
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 8 (6) , 673-701
Pyrrolobenzimidazoles in cancer treatment
This review presents a discussion of the design, chemistry, cytotoxicity and antitumour activity of agents based on the pyrrolobenzimidazole or azomitosene ring system. The focus is the 6-aziridinylquinone derivatives (PBIs) and 6-acetamidoquinone derivatives (APBIs) of this ring system (see Figure 1). Comparisons will be made with related benzimidazole and indole-based antitumour agent systems reported in the patent literature. The pyrrolobenzimidazoles will be shown to represent a new and useful class of antitumour agent with advantages over other such agents. The 6-aziridinyl derivatives (PBIs) alkylate and cleave DNA upon two-electron reduction as a result of phosphate alkylation by the protonated aziridine ring. In contrast, the 6-acetamido quinone derivatives (APBIs) do not require reductive activation to exert cytotoxicity. The 6-acetamido quinone derivatives act as DNA intercalating agents and inhibit the first step of topoisomerase II-mediated DNA relaxation. Some PBIs were found to exhibit high ...
- 1 June 1998
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 8 (6) , 673-701
Pyrrolobenzimidazoles in cancer treatment
This review presents a discussion of the design, chemistry, cytotoxicity and antitumour activity of agents based on the pyrrolobenzimidazole or azomitosene ring system. The focus is the 6-aziridinylquinone derivatives (PBIs) and 6-acetamidoquinone derivatives (APBIs) of this ring system (see Figure 1). Comparisons will be made with related benzimidazole and indole-based antitumour agent systems reported in the patent literature. The pyrrolobenzimidazoles will be shown to represent a new and useful class of antitumour agent with advantages over other such agents. The 6-aziridinyl derivatives (PBIs) alkylate and cleave DNA upon two-electron reduction as a result of phosphate alkylation by the protonated aziridine ring. In contrast, the 6-acetamido quinone derivatives (APBIs) do not require reductive activation to exert cytotoxicity. The 6-acetamido quinone derivatives act as DNA intercalating agents and inhibit the first step of topoisomerase II-mediated DNA relaxation. Some PBIs were found to exhibit high ...
- 1 April 1996
- Published by Georg Thieme Verlag KG in Synlett
- Vol. 1996 (04) , 297-309
The Organic Chemistry of the Pyrrolo[1,2-a]benzimidazole Antitumor Agents. An Example of Rational Drug Design
Work in our laboratory has led to the development of the pyrrolo[1,2-a]benzimidazole-based antitumor agents. There are three structural classes of these agents: the 6-aziridinyl analogues (PBIs), the 6-acetamido analogues (APBIs), and the imino-6-acetamido analogues (imino-APBIs). These agents were prepared by multistep syntheses, all of which started with a pyrrolo[1,2-a]benzimidazole ring forming reaction utilizing the ”t-amino effect”. Enantiospecific synthesis were also carried out employing amino acids of known configuration and an ”internal” Phillips reaction. The chemistry of the rest of the steps leading to the PBIs, APBIs, and the imino-APBIs is presented. The aziridinyl ring of the PBIs is activated as an alkylating agent upon quinone reduction. In addition, the aziridinyl ring also traps a proton. This unprecedented reaction is very likely a [1,5]sigmatropic shift. Reductive alkylation of mononucleotides and DNA by PBIs result in alkylation of the phosphate oxygen anion. The reaction at this site is attributed to electronic factors as well as hydrogen bonding in the DNA major groove. The DNA alkylation reaction and resulting cleavage are likely responsible for the antitumor activity observed in the PBIs. The chemical events leading to APBI and imino-APBI antitumor activity are currently under study.
- 1 April 1996
- Published by Georg Thieme Verlag KG in Synlett
- Vol. 1996 (04) , 297-309
The Organic Chemistry of the Pyrrolo[1,2-a]benzimidazole Antitumor Agents. An Example of Rational Drug Design
Work in our laboratory has led to the development of the pyrrolo[1,2-a]benzimidazole-based antitumor agents. There are three structural classes of these agents: the 6-aziridinyl analogues (PBIs), the 6-acetamido analogues (APBIs), and the imino-6-acetamido analogues (imino-APBIs). These agents were prepared by multistep syntheses, all of which started with a pyrrolo[1,2-a]benzimidazole ring forming reaction utilizing the ”t-amino effect”. Enantiospecific synthesis were also carried out employing amino acids of known configuration and an ”internal” Phillips reaction. The chemistry of the rest of the steps leading to the PBIs, APBIs, and the imino-APBIs is presented. The aziridinyl ring of the PBIs is activated as an alkylating agent upon quinone reduction. In addition, the aziridinyl ring also traps a proton. This unprecedented reaction is very likely a [1,5]sigmatropic shift. Reductive alkylation of mononucleotides and DNA by PBIs result in alkylation of the phosphate oxygen anion. The reaction at this site is attributed to electronic factors as well as hydrogen bonding in the DNA major groove. The DNA alkylation reaction and resulting cleavage are likely responsible for the antitumor activity observed in the PBIs. The chemical events leading to APBI and imino-APBI antitumor activity are currently under study.